The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users. Taylor Leamey wrote about all things wellness for CNET, specializing in ...
DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...
“The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “By listening to the needs of our users, ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase for the first time its new global ...
(COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring ...
DexCom reported mixed Q2 results with an earnings beat, but revenue missed expectations. The company lowered its full-year revenue guidance. DexCom's steep valuation is only justifiable with sustained ...
Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring ...
DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...
(Reuters) -Dexcom shares closed more than 40% lower on Friday after the glucose monitor maker slashed its annual revenue forecast due to the fallout from a salesforce revamp, prompting some analysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback